Novel targeted therapies for metastatic breast cancer

Khalid Jazieh; Ruth Bell; Nayan Agarwal; Jame Abraham

doi:10.21037/atm.2020.03.43

Novel targeted therapies for metastatic breast cancer

Ann Transl Med. 2020 Jul;8(14):907. doi: 10.21037/atm.2020.03.43.

Authors

Khalid Jazieh¹, Ruth Bell¹, Nayan Agarwal¹, Jame Abraham²

Affiliations

¹ Department of Internal Medicine, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
² Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

Abstract

Metastatic breast cancer (mBC) continues to be a leading cause of cancer-related death in women. Even though mortality rates have improved over recent years, the 5-year survival rate of advanced BC is still at only 27%. As researchers and clinicians attempt to tackle this challenge, there has been extensive research and many trials studying treatment options for BC patients with metastatic disease, with numerous new therapies being discovered as a result. We review the most pertinent novel agents to enter the scope of BC treatment, including CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, immunotherapy, PARP inhibitors, and more.

Keywords: Breast cancer (BC); novel agents; targeted therapy.

Publication types

Review